Stocks · News reference

Maze Therapeutics Announces Presentation Of Updated Phase 2 MZE829 Kidney Disease Data At ASN Kidney Week On October 24

Oct 6, 2026, 8:06 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 19, 2026, 12:16 PMBenzinga Newsdesk
Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75
Canaccord Genuity analyst Whitney Ijem initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $75.
MAZE
SEC EDGAROct 16, 2026, 8:05 PMSEC EDGAR
8-K filing — Maze Therapeutics, Inc. (MAZE)
Filed: 2026-10-16 AccNo: 0001193125-26-424067 Size: 185 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
MAZE
BenzingaSep 24, 2026, 11:31 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target
HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $110 price target.
MAZE